Targeting RAD51-BRCA2 interaction in the search for novel anticancer and chemosensitizer drug candidates

Schipani, Fabrizio (2018) Targeting RAD51-BRCA2 interaction in the search for novel anticancer and chemosensitizer drug candidates, [Dissertation thesis], Alma Mater Studiorum Università di Bologna. Dottorato di ricerca in Scienze biotecnologiche e farmaceutiche, 30 Ciclo. DOI 10.6092/unibo/amsdottorato/8558.
Documenti full-text disponibili:
[img]
Anteprima
Documento PDF (English) - Richiede un lettore di PDF come Xpdf o Adobe Acrobat Reader
Disponibile con Licenza: Salvo eventuali più ampie autorizzazioni dell'autore, la tesi può essere liberamente consultata e può essere effettuato il salvataggio e la stampa di una copia per fini strettamente personali di studio, di ricerca e di insegnamento, con espresso divieto di qualunque utilizzo direttamente o indirettamente commerciale. Ogni altro diritto sul materiale è riservato.
Download (8MB) | Anteprima

Abstract

Genome integrity is constantly affected by DNA damage and replication errors due to exogenous and endogenous sources. Cells have developed several strategies to counteract these threats detecting DNA damages and mediating its repair through different mechanisms depending on the specificity of the DNA lesion. Cancer cells are more sensitive to these insults compared to normal cells and most therapeutic strategy indeed rely on inducing specific lethal DNA damages. The urgent need for new therapeutic strategies in cancer treatment is due to the frequent development of resistance to therapeutic induced DNA damage. Through a multidisciplinary project, comprising a computational, a synthetic, a biology as well as a biophysical contribution, we aim at applying a synthetic lethality approach in cancer cell therapy by preventing, with small molecules, the viable hRAD51-BRCA2 interaction. The latter interaction plays a key role in the repair of double strand breaks (DSBs) within the homologous recombination (HR) pathway. The leading idea of our project is mimicking the synthetic lethality induced in BRCA2 defective oncology patients by olaparib, a poly ADP ribose polymerase (PARP) inhibitor. We aim at increasing cancer cells sensitivity to PARPi and at broadening PARPi applicability by administering, in combination with the latter inhibitors, hRAD51-BRCA2 small molecules disruptors also to individuals without BRCA2 mutations. The goal of my PhD research project is the characterization of the hRAD51-BRCA2 interaction through a biophysical approach, in order to gain kinetic and thermodynamic insights on this critical junction of the HR pathway, and through a structural approach, to elucidate the atomic details of the interaction. My research work is concurrently a critical support for the overall project, which aims at the development of a new drug and at the validation of a broaden applicability of the synthetic lethality concept.

Abstract
Tipologia del documento
Tesi di dottorato
Autore
Schipani, Fabrizio
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
30
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
RAD51; BRCA2; recombinant proteins; protein-protein interaction; synthetic lethality; homologous recombination; NMR fragment based screening; biophysical analyses; MST; SPR; small molecules;
URN:NBN
DOI
10.6092/unibo/amsdottorato/8558
Data di discussione
3 Maggio 2018
URI

Altri metadati

Statistica sui download

Gestione del documento: Visualizza la tesi

^